|
original article |
Date |
Title |
Authors All Authors |
1 |
[GO] |
2025―Jan―09 |
Identification and Validation of Potential Biomarkers and Therapeutic Targets of COVID-19-related Depression |
Peng Qi, Mengjie Huang, Haiyan Zhu |
2 |
[GO] |
2024―Aug―12 |
Analysis of Key Genes Related to Systemic Lupus Erythematosus and COVID-19 |
Rui Guan, Jing Yu, Jiannan Zheng, Yeyu Zhao, Bolun Zhang, Min Wang, Mingli Gao |
3 |
[GO] |
2024―Jun―13 |
Prospects for the Protective Mechanisms and Compounds of Bufei Huoxue Capsule against COVID-19 Convalescence: Evaluation of Integrating
UHPLC-HRMS Analysis and Network Pharmacology Strategy |
Yizi Xie, Yi Xie, Cheng-Xin Liu, Chen-Wen Peng, Xue-Ying Lin, Hui-Ting Huang, et al. (+4) Shao-Feng Zhan, Xiao-Hong Liu, Hang Li, Xiu-Fang Huang |
4 |
[GO] |
2023―Nov―14 |
Network Pharmacology and Experimental Validation of Qingwen Baidu
Decoction Therapeutic Potential in COVID-19-related Lung Injury |
Ju Yang, Zhao Zhang, Honghong Liu, Jiawei Wang, Shuying Xie, Pengyan Li, et al. (+5) Jianxia Wen, Shizhang Wei, Ruisheng Li, Xiao Ma, Yanling Zhao |
5 |
[GO] |
2023―Mar―31 |
The potential effect of dapsone on the inflammatory reactions in Covid-19: Staggering view |
Engy Elekhnawy, Hayder M. Al-kuraishy, Ali I. Al-Gareeb, Athanasios Alexiou, Gaber El-saber Batiha |
6 |
[GO] |
2022―Dec―04 |
Molecular Docking and Virtual Screening Based Prediction of Drugs for COVID-19 |
|
7 |
[GO] |
2022―Dec―04 |
The Antiviral and Antimalarial Drug Repurposing in Quest of Chemotherapeutics to Combat COVID-19 Utilizing Structure-Based Molecular Docking |
Sisir Nandi |
8 |
[GO] |
2022―Dec―04 |
Lead Finding from Selected Flavonoids with Antiviral (SARS-CoV-2) Potentials Against COVID-19: An In-silico Evaluation |
|
9 |
[GO] |
2022―Dec―04 |
Mechanistic Insights to the Binding of Antibody CR3022 Against RBD from SARS-CoV and HCoV-19/SARS-CoV-2: A Computational Study |
Wei Yu |
10 |
[GO] |
2022―Dec―04 |
Tinocordiside from Tinospora cordifolia (Giloy) May Curb SARS-CoV-2 Contagion by Disrupting the Electrostatic Interactions between Host ACE2 and Viral S-Protein Receptor Binding Domain |
|
11 |
[GO] |
2022―Dec―04 |
Discovery of Potent SARS-CoV-2 Inhibitors from Approved Antiviral Drugs via Docking and Virtual Screening |
|
12 |
[GO] |
2022―Dec―04 |
Potential Leads from Liquorice Against SARS-CoV-2 Main Protease using Molecular Docking Simulation Studies |
|
13 |
[GO] |
2022―Nov―11 |
Insights into the structural complexities of SARS-CoV-2 for therapeutic and vaccine development |
Manaf AlMatar, Aizi Nor Mazila Ramli, Choong Xin Yi |
14 |
[GO] |
2022―Nov―05 |
The Understanding of the Potential Linkage between COVID-19, Type-2
Diabetes, and Cancer(s) Could Help in Better Drug Targets and
Therapeutics |
Mohammad Mobashir |
15 |
[GO] |
2022―Oct―18 |
Exploring the Potential Mechanism of Shufeng Jiedu Capsule for Treating COVID-19 by Comprehensive Network Pharmacological Approaches and Molecular Docking Validation |
Zhenjie Zhuang |
16 |
[GO] |
2022―Oct―18 |
Perspective on the COVID-19 Coronavirus Outbreak |
Gerald Lushington |
17 |
[GO] |
2022―Oct―18 |
Analysis of Chinese Herbal Formulae Recommended for COVID-19 in Different Schemes in China: A Data Mining Approach |
LiWei Yin |
18 |
[GO] |
2022―Oct―18 |
Theoretical Study of the Molecular Mechanism of Maxingyigan Decoction Against COVID-19: Network Pharmacology-based Strategy |
Mingzhu Wang |
19 |
[GO] |
2022―Oct―18 |
Mechanistic Insights to the Binding of Antibody CR3022 Against RBD from SARS-CoV and HCoV-19/SARS-CoV-2: A Computational Study |
Wei Yu |
20 |
[GO] |
2022―Oct―10 |
Bioinformatics analysis to identify intersection genes, associated pathways and therapeutic drugs between COVID-19 and Oral candidiasis |
Zhihui Liu, Liuqing Yang, Jinling Yu, Handan Huang, Lu Tao, Ying Gao, Jingjing Yao |
21 |
[GO] |
2022―Aug―30 |
Synthesis, Molecular Docking, c-Met inhibitions of 2,2,2-Trichloro-ethylidene-cyclohexane-1,3-dione Derivatives Together With Their Application as Target SARS-CoV-2 main Protease (Mpro) And as Potential Anti-Covid-19 |
Rafat M. Mohareb, Fahad M. Almutairi, Abdo A. Elfiky, Mahmoud A.A. Mahmoud, Wagnat W. Wardakhan, Mervat S. Mohamed, Ali Saber Abdelhameed |
22 |
[GO] |
2022―Aug―19 |
In silico identification of novel SARS-CoV-2 main protease and non-structural protein 13 (nsp13) inhibitors through consensus docking and free binding energy calculations. |
Emilio Mateev, Maya Georgieva, Alexander Zlatkov |
23 |
[GO] |
2022―Aug―17 |
Evaluations of FDA-approved drugs targeting 3CLP of SARS-CoV-2 employing a repurposing strategy. |
Syed Sayeed Ahmad, Mohammad Khalid |
24 |
[GO] |
2022―Aug―17 |
Molecular interactions of Zyesami with the SARS-CoV-2 nsp10/nsp16 protein complex |
Sultan F. Alnomasy, Bader S. Alotaibi, Ziyad M. Aldosari, Ahmed H. Mujamammi, Ahmad Alzamami, Pragya Anand, et al. (+3) Yusuf Akhter, Farhan R Khan, Mohammad R. Hasan |
25 |
[GO] |
2022―Aug―05 |
Lead Finding from Selected Flavonoids with Antiviral (SARS-CoV-2) Potentials Against COVID-19: An In-silico Evaluation |
Uma Sankar-Gorla |
26 |
[GO] |
2022―Aug―05 |
Tinocordiside from Tinospora cordifolia (Giloy) May Curb SARS-CoV-2 Contagion by Disrupting the Electrostatic Interactions between Host ACE2 and Viral S-Protein Receptor Binding Domain |
Acharya Balkrishna |
27 |
[GO] |
2022―Jul―15 |
Molecular Docking and Virtual Screening Based Prediction of Drugs for COVID-19 |
Sekhar Talluri |
28 |
[GO] |
2022―Jul―15 |
Lead Finding from Selected Flavonoids with Antiviral (SARS-CoV-2) Potentials Against COVID-19: An In-silico Evaluation |
Uma Sankar Gorla |
29 |
[GO] |
2022―Jul―15 |
Tinocordiside from Tinospora cordifolia(Giloy) May Curb SARS-CoV-2 Contagion by Disrupting the Electrostatic Interactions between Host ACE2 and Viral S-Protein Receptor Binding Domain |
Anurag Varshney |
30 |
[GO] |
2022―Jul―15 |
Discovery of Potent SARS-CoV-2 Inhibitors from Approved Antiviral Drugs via Docking and Virtual Screening |
Samir Chtita |
31 |
[GO] |
2022―Jul―14 |
Analysis of the molecular mechanism of Huangqi herb treating COVID-19 with myocardial injury by pharmacological tools, programming software and molecular docking |
Yan Zhou, Yuguang Chu, Jingjing Shi, Yuanhui Hu |
32 |
[GO] |
2022―Jun―30 |
An Overview on Immunity Booster Foods in Coronavirus Disease (COVID-19) |
Nusrat Sahiba, Ayushi Sethiya, Dinesh K. Agarwal, Shikha Agarwal |
33 |
[GO] |
2022―Jun―08 |
South African (501Y.V2) and the United Kingdom (B.1.1.7) SARS-CoV-2 spike (S) protein variants demonstrate a higher binding affinity to ACE2 |
Anwar Mohammad, Jehad Abubaker, Fahd Al-Mulla |
34 |
[GO] |
2022―May―11 |
Potential of 24-Propylcholestrol as Immunity Inducer against Infection of COVID-19 Virus: In Silico Study Immunomodulatory Drugs |
Dikdik Kurnia, Ika Wiani, Achmad Zainuddin, Devi Windaryanti, Christine Sondang Gabriel |
35 |
[GO] |
2022―Apr―28 |
Neglected Tropical Diseases (NTDs) and COVID-19 Pandemic in Africa: Special Focus on Control Strategies |
Abdullahi Tunde Aborode, Emmanuel Adebowale Fajemisin, Emmanuel Ademola Aiyenuro, Muhammed Alakitan, Matthew Olaide Ariwoola, Jegede Oluwatoyin Imisioluwa, et al. (+2) Raheemt Rafiu, Athanasios Alexiou |
36 |
[GO] |
2022―Apr―25 |
Can the Written Word Fuel Pharmaceutical Innovation? Part 1. an emerging vista from von Economo to COVID-19 |
Gerald H. Lushington, Mary I. Zgurzynski |
37 |
[GO] |
2022―Apr―18 |
Favipiravir in SARS-CoV-2 infection: Is it Worthwhile? |
Gaber El-Saber Batiha, Mohamed Moubarak, Hazem M. Shaheen, Ali Muhammad Zakariya, Ibe Michael Usman, Abdur Rauf, et al. (+6) Achyut Adhikari, Abhijit Dey, Athanasios Alexiou, Helal F. Hetta, Ali I. Al-Gareeb, Hayder M. Al-kuraishy |
38 |
[GO] |
2022―Mar―16 |
Covid-19 Vaccines available in India |
Mohammad Mukim, Pratishtha Sharma, Mohsina F.P, Faheem I.P, Rajiv Kukkar, Rakesh Patel |
39 |
[GO] |
2022―Mar―16 |
Crosstalk between SARS-CoV-2 Infection and Type II Diabetes |
Asim Azhar, Wajihul Hasan Khan, Khaled Al-hosaini, Qamar Zia, Mohammad Amjad Kamal |
40 |
[GO] |
2022―Mar―01 |
Therapeutic mechanism of Xiaoqinglong decoction against COVID-19 based on network pharmacology and molecular docking technology |
Hai-Li Li, Jian-Peng Zhou, Jing-Min Deng |
41 |
[GO] |
2022―Feb―10 |
Repurposing Ayush-64 for COVID-19: A Computational Study Based on Network Pharmacology and Molecular Docking |
Abdul Nazeer K.A. |
42 |
[GO] |
2022―Jan―28 |
Natural products against COVID-19 inflammation: a mini-review |
Simone Mendes Lopes, Herbert Igor Rodrigues de Medeiros, Marcus Tullius Scotti, Luciana Scotti |
43 |
[GO] |
2022―Jan―13 |
Computational Chemistry in the Fight Against SARS-CoV-2. |
Abbas Khan, Dong-Qing Wei |
44 |
[GO] |
2021―Dec―01 |
Can We Use mTOR Inhibitors for COVID-19 Therapy? |
Ina Y. Aneva, Solomon Habtemariam, Maciej Banach, Parames C. Sil, Kasturi Sarkar, Adeleh Sahebnasagh, et al. (+3) Mohammad Amjad Kamal, Maryam Khayatkashani, Hamid Reza Khayat Kashani |
45 |
[GO] |
2021―Nov―23 |
Potential Papain-like Protease Inhibitors against COVID-19: A Comprehensive In Silico Based Review |
Neetu Agrawal, Shilpi Pathak, Ahsas Goyal |
46 |
[GO] |
2021―Sep―17 |
Polyphenolic Natural Products Active In Silico against SARS-CoV-2 Spike Receptor Binding Domains and Non-Structural Proteins - A Review |
Mark Tristan Quimque, Kin Israel Notarte, Xela Amor Adviento, Mikhail Harvey Cabunoc, Von Novi de Leon, Felippe Steven Louis delos Reyes, et al. (+10) Eiron John Lugtu, Joe Anthony Manzano, Sofia Nicole Monton, John Emmanuel Muñoz, Katherine Denise Ong, Delfin Yñigo Pilapil IV, Vito Roque III, Sophia Morgan Tan, Justin Allen Lim, Allan Patrick Macabeo |
47 |
[GO] |
2021―Aug―12 |
COVID-19: Finally on wane, with reduced lethality |
Deepak Sharma |
48 |
[GO] |
2021―Aug―06 |
Current perspective of COVID-19 on neurology: A mechanistic insight |
Rajesh Kumar, Seetha Harilal, Leena K Pappachan, P R Roshni, Bijo Mathew |
49 |
[GO] |
2021―Aug―05 |
Role of potential COVID-19 immune system associated genes and the potential pathways linkage with type-2 diabetes |
Nawal Helmi, Dalia Alammari, Mohammad Mobashir |
50 |
[GO] |
2021―Jul―12 |
COVID-19 candidate genes and pathways potentially share the association with lung cancer |
Afnan M. Alnajeebi, Hend F.H. Alharbi, Walla Alelwani, Nouf A. Babteen, Wafa Alansari, Ghalia Shamlan, Areej A. Eskandrani |
51 |
[GO] |
2021―Jun―02 |
Identification of Generalized Peptide Regions for Designing Vaccine Effective for All Significant Mutated Strains of SARS-CoV-2 |
Subhamoy Biswas, Smarajit Manna, Tathagata Dey, Shreyans Chatterjee, Sumanta Dey |
52 |
[GO] |
2021―Feb―04 |
An Urgent Industrial Scheme both for Total Synthesis, and for Pharmaceutical Analytical Analysis of Umifenovir as an Anti-Viral API for Treatment of COVID-19 |
Akbar Dadras, Mohammad Amin Rezvanfar, Abolghasem Beheshti, Sedigheh Sadat Naeimi, Seyyed Amir Siadati |
53 |
[GO] |
2020―Nov―24 |
Catechin Derivatives as Inhibitor of COVID-19 Main Protease (Mpro): Molecular Docking studies unveils an opportunity against CORONA |
Muhammad Nouman Arif |
54 |
[GO] |
2020―Nov―11 |
In-silico analysis of angiotensin converting enzyme 2 (ACE2) of livestock, pet and poultry animals to determine its susceptibility to SARS-CoV- 2 infection |
Aman Kumar, Anil Panwar, Kanisht Batra, Sachinandan Dey, Sushila Maan |
55 |
[GO] |
2020―Nov―11 |
Tinocordiside from Tinospora cordifolia (Giloy) May Curb SARS-CoV-2 Contagion by Disrupting the Electrostatic Interactions between Host ACE2 and Viral S-Protein Receptor Binding Domain |
Acharya Balkrishna, Subarna Pokhrel, Anurag Varshney |
56 |
[GO] |
2020―Nov―06 |
A Computational Approach for Identifying Potential Phytochemicals Against Non-structural Protein 1 (Nsp1) of SARS-CoV-2 |
Alamgir Hossain |
57 |
[GO] |
2020―Nov―03 |
Exploring the Potential Mechanism of Shufeng Jiedu Capsule for Treating COVID-19 by Comprehensive Network Pharmacological Approaches and Molecular Docking Validation |
Zhenjie Zhuang, Xiaoying Zhong, Huanhuan Zhang, Huiqi Chen, Boxiang Huang, Dongqun Lin, Junmao Wen |
58 |
[GO] |
2020―Oct―27 |
Mechanistic Insights to the Binding of Antibody CR3022 Against RBD from SARS-CoV and HCoV-19/SARS-CoV-2: A Computational Study |
Wei Yu, Xiaomin Wu, Jiayi Ren, Xiaochun Zhang, Yueming Wang, Chengming Li, et al. (+6) Wenwen Xu, Weihong Zheng, Huaxin Liao, Xiaohui Yuan, Jason Li, Gang Li |
59 |
[GO] |
2020―Oct―01 |
Analysis of Chinese herbal formulae recommended for COVID-19 in different schemes in China: A data mining Approach |
LiWei Yin, YaCen Gao, ZiPing Li, MengYu Wang, KaiXin Chen |
60 |
[GO] |
2020―Sep―15 |
In silico modeling of small molecule carboxamides as inhibitors of SARS-CoV 3CL protease: An approach towards combating COVID-19 |
Pathan Mohsin Khan, Vinay Kumar, Kunal Roy |
61 |
[GO] |
2020―Sep―03 |
Discovery of Some Antiviral Natural products to fight against Novel Corona Virus (SARS-CoV-2) using Insilico approach |
Ashish Shah, Vaishali Patel, Bhumika Parmar |
62 |
[GO] |
2020―Aug―30 |
Molecular Docking Studies of Bioactive Nicotiflorin against 6W63 Novel Coronavirus 2019 (COVID-19) |
Raghvendra Dubey, Kushagra Dubey |
63 |
[GO] |
2020―Aug―24 |
The Antiviral and Antimalarial Drug Repurposing in Quest of Chemotherapeutics to Combat COVID-19 Utilizing Structure-Based Molecular Docking |
Sisir Nandi, Mohit Kumar, Mridula Saxena, Anil Kumar Saxena |
64 |
[GO] |
2020―Aug―21 |
Lead Finding from Selected Flavonoids with Antiviral (SARS-CoV-2) Potentials against COVID-19: An in-silico Evaluation |
Uma Sankar Gorla, GSN Koteswara Rao, Uma Sankar Kulandaivelu, Rajasekhar Reddy Alavala, Siva Prasad Panda |
65 |
[GO] |
2020―Aug―19 |
Potential Leads from Liquorice against SARS-CoV-2 Main Protease using Molecular Docking Simulation Studies |
Saurabh K. Sinha, Satyendra K. Prasad, Md Ataul Islam, Sushil K. Chaudhary, Shashikant Singh, Anshul Shakya |
66 |
[GO] |
2020―Aug―14 |
Molecular Docking and Virtual Screening based prediction of drugs for COVID-19 |
Sekhar Talluri |
67 |
[GO] |
2020―Aug―08 |
Theoretical Study of the Molecular Mechanism of Maxingyigan Decoction Against COVID-19: Network Pharmacology-based Strategy |
Mingzhu Wang, Deyu Fu, Lei Yao, Jianhua Li |
68 |
[GO] |
2020―Aug―05 |
Discovery of Potent SARS-CoV-2 Inhibitors from Approved Antiviral Drugs via Docking Screening |
Samir Chtita, Assia Belhassan, Adnane Aouidate, Salah Belaidi, Mohammed Bouachrine, Tahar Lakhlifi |
69 |
[GO] |
2020―Jul―29 |
Could Targeting HMGB1 be useful for the Clinical Management of COVID-19 Infection? |
Mustafa Çelebier, İbrahim Celalettin Haznedaroğlu |
70 |
[GO] |
2020―Jul―27 |
Viral Evolution will Automatically Resolve COVID-19 Pandemic |
Deepak Sharma |
71 |
[GO] |
2020―Jul―16 |
Doctoral Degree Surplus and Dwindling Quality: A Perilous Blend for Young Scientists in Tackling COVID-19 Like Pandemics |
Deepak Sharma |
72 |
[GO] |
2020―Apr―08 |
Perspective on the COVID-19 Coronavirus Outbreak |
Gerald H. Lushington |